• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticoagulant activity of edoxaban in patients with cirrhosis.

作者信息

Bos Sarah, Schreuder Tim, Blokzijl Hans, Adelmeijer Jelle, Lisman Ton, Kamphuisen Pieter W

机构信息

Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, and.

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

出版信息

Blood. 2020 Sep 24;136(13):1561-1564. doi: 10.1182/blood.2020005319.

DOI:10.1182/blood.2020005319
PMID:32458002
Abstract
摘要

相似文献

1
Anticoagulant activity of edoxaban in patients with cirrhosis.依度沙班在肝硬化患者中的抗凝活性。
Blood. 2020 Sep 24;136(13):1561-1564. doi: 10.1182/blood.2020005319.
2
Point-of-care testing of coagulation in patients treated with edoxaban.依度沙班治疗患者的即时凝血检测。
J Thromb Thrombolysis. 2020 Oct;50(3):632-639. doi: 10.1007/s11239-020-02143-2.
3
Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.口服直接因子Xa抑制剂依度沙班对常规凝血检测、狼疮抗凝物及抗Xa检测的影响
Scand J Clin Lab Invest. 2018 Nov-Dec;78(7-8):575-583. doi: 10.1080/00365513.2018.1522664. Epub 2018 Oct 2.
4
Measuring Direct Oral Anticoagulants.测量直接口服抗凝剂。
Methods Mol Biol. 2017;1646:217-225. doi: 10.1007/978-1-4939-7196-1_18.
5
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.在 ENGAGE AF-TIMI 48 试验中，将内源性因子 Xa 活性（一种具有生物学相关性的药效动力学标志物）与依度沙班的血浆浓度和临床结局联系起来。
Circulation. 2018 Oct 30;138(18):1963-1973. doi: 10.1161/CIRCULATIONAHA.118.033933.
6
[A study of usefulness for portal vein thrombus with edoxaban].[依度沙班治疗门静脉血栓的有效性研究]
Nihon Shokakibyo Gakkai Zasshi. 2016 Mar;113(3):439-40. doi: 10.11405/nisshoshi.113.439.
7
The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.三因子凝血酶原复合物浓缩物对因子 Xa 抑制剂依度沙班抗凝作用的影响。
Thromb Res. 2015 Oct;136(4):825-31. doi: 10.1016/j.thromres.2015.07.012. Epub 2015 Jul 16.
8
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].Xa因子直接抑制剂的药理及临床特性：利伐沙班、阿哌沙班、依度沙班和贝曲沙班
J Mal Vasc. 2014 May;39(3):183-94. doi: 10.1016/j.jmv.2014.02.001. Epub 2014 Mar 18.
9
A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty.一种用于测定Xa抑制剂依度沙班的定量液相色谱/串联质谱法及其在全膝关节置换术后患者中的药代动力学应用。
Biomed Chromatogr. 2018 Jun;32(6):e4213. doi: 10.1002/bmc.4213. Epub 2018 Mar 25.
10
Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.采用全自动抗因子 Xa 显色法测定人血浆中依度沙班等效浓度。
Thromb Res. 2017 Jul;155:121-127. doi: 10.1016/j.thromres.2017.05.005. Epub 2017 May 7.

引用本文的文献

1
Prediction and prevention of post-procedural bleedings in patients with cirrhosis.肝硬化患者术后出血的预测与预防
Clin Mol Hepatol. 2025 Feb;31(Suppl):S205-S227. doi: 10.3350/cmh.2024.0928. Epub 2025 Feb 18.
2
Direct oral anticoagulants in cirrhosis: Rationale and current evidence.直接口服抗凝剂在肝硬化中的应用：理论依据与当前证据。
JHEP Rep. 2024 May 9;6(8):101116. doi: 10.1016/j.jhepr.2024.101116. eCollection 2024 Aug.
3
Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data.
基于药代动力学、药效学和安全性数据的系统评价，为肝硬化患者安全使用直接口服抗凝剂的建议。
Eur J Clin Pharmacol. 2024 Jun;80(6):797-812. doi: 10.1007/s00228-024-03648-y. Epub 2024 Mar 2.
4
Patients with metabolic dysfunction-associated steatotic liver disease have preserved responses to antiplatelet drugs.患有代谢功能障碍相关脂肪性肝病的患者对抗血小板药物仍有反应。
Res Pract Thromb Haemost. 2023 Oct 10;7(7):102217. doi: 10.1016/j.rpth.2023.102217. eCollection 2023 Oct.
5
Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis.在肝硬化患者中，治疗剂量的直接口服抗凝剂会使国际标准化比值和终末期肝病模型评分出现具有临床意义的升高。
Res Pract Thromb Haemost. 2023 Jan 14;7(1):100052. doi: 10.1016/j.rpth.2023.100052. eCollection 2023 Jan.
6
Pathophysiology and management of bleeding and thrombosis in patients with liver disease.肝病患者出血和血栓形成的病理生理学和管理。
Int J Lab Hematol. 2022 Sep;44 Suppl 1(Suppl 1):79-88. doi: 10.1111/ijlh.13856. Epub 2022 Apr 21.
7
Safety of direct oral anticoagulants in patients with advanced liver disease.直接口服抗凝剂在晚期肝病患者中的安全性。
Liver Int. 2021 Sep;41(9):2159-2170. doi: 10.1111/liv.14992. Epub 2021 Jul 10.
8
Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis.肝素在住院肝硬化患者中有足够的体外抗凝效果。
J Thromb Haemost. 2021 Jun;19(6):1472-1482. doi: 10.1111/jth.15296. Epub 2021 Apr 9.